| Nevro is a medical device company that has developed and commercialized the Senza® spinal cord stimulation system, a neuromodulation platform for the treatment of chronic pain, with the Senza® Omnia platform as an addition to the Senza family of products. Co.'s HF10 therapy, delivered by its Senza system is designed to treat back pain and leg pain. The Senza system is approved to create electrical impulses and its HF10 therapy for pain relief without paresthesia. HF10 therapy delivers waveforms with a programming algorithm. Senza is consisted of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician programmer, a patient remote control and a mobile charger. We show 32 historical shares outstanding datapoints in our coverage of NVRO's shares outstanding history.|
Understanding the changing numbers of NVRO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NVRO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NVRO by allowing them to research NVRO shares outstanding history
as well as any other stock in our coverage universe.